Buradasınız

Anasayfa » Content

Cisplatin’e Bağlı Böbrek Toksisitesi ve Sentetik Oral Prostaglandin E1 Analoğunun Etkinliğinin Değerlendirilmesi

Cisplatin-Induced Renal Toxicity and Evaluation of the Efficacy of Synthetic Oral Prostaglandin E1 Analogue

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Despite the demonstration of the protective effects of misoprostol, an oral prostaglandin E1 analogue, on the nephrotoxicity of non-steroidal antiinflammatory drugs (NSAID) and cyclosporine, its role in cisplatin nephrotoxicity has not been investigated. In our study, we planned to investigate cisplatin-induced acute renal failure and the efficacy of misoprostol on acute cisplatin nephrotoxicity. For this purpose, 28 lung cancer patients who had been planned to receive the cisplatin+etoposide chemotherapy regimen were included in the study. Patients then were divided into two groups. In addition to chemotherapy, Misoprostol group received misoprostol at the dose of 100 µg qid during the study. Control group received only chemotherapy. Renal functions were evaluated in both groups before the onset of chemotherapy and 2nd and 6th days of chemotherapy. In conclusion, it was demonstrated that misoprostol could not produce any protective effect on the functional disturbances due to cisplatin administration.
Bookmark/Search this post with
Abstract (Original Language): 
Bir oral prostaglandin E1 analoğu olan misoprostolün steroid olmayan antienflamatuar ilaçlar (NSAID) ve siklosporin nefrotoksisitesinde protektif etkisi olduğu gösterilmesine karşın, cisplatin nefrotoksisitesindeki rolü incelenmemiştir. Çalışmamızda cisplatine bağlı gelişen akut böbrek yetmezliğinin ve misoprostolün akut cisplatin nefrotoksisitesindeki etkinliğinin incelenmesi amaçlanmıştır. Bu amaçla cisplatin+etoposid kemoterapi rejimi alması planlanan 28 akciğer kanserli hasta çalışmaya dahil edildi. Hastalar iki gruba ayrıldı. Misoprostol grubu kemoterapinin yanısıra çalışma süresince günde 4 kez 100 µg dozda misoprostol aldı. Kontrol grubu sadece kemoterapi aldı. Her iki grupta renal fonksiyonlar kemoterapi başlamasından önce ve kemoterapinin 2. ve 6. günlerinde değerlendirildi. Sonuç olarak, cisplatin kullanımına bağlı gelişen fonksiyonel bozukluklarda misoprostolün koruyucu etkinlik gösteremediği saptandı.
FULL TEXT (PDF): 
PDF icon arastirmax-cisplatine-bagli-bobrek-toksisitesi-sentetik-oral-prostaglandin-e1-analogunun-etkinliginin-degerlendirilmesi.pdf
  • 2
17-20
  • Turkish

REFERENCES

References: 

1. Anand AJ, Bashey B. Newer insights into cisplatin
nephrotoxicity. Ann Pharmacother 1993;23:1519-27.
2. Weiss RB. Miscellaneous Toxcities. In: DeVita VT, Hellman S,
Rosenberg SA (eds). Cancer-Principles&Practice of
Oncology. Philadelphia: Lippincott Williams&Wilkins;
2001. pp2964-76.
3. Zhang JG, Lindup WE. Cisplatin nephrotoxicity: Decreases in
mitochondrial protein sulphydryl concentration and
calcium uptake by mitochondria from rat renal cortical
slices. Biochem Pharmacol 1994;47(7):1127-35.
4. Brady HR, Zeidel ML, Kone BC, Giebisch G, Gullans SR.
Differantial actions of cisplatin on proksimal tubule and
inner medullary collecting duct cells. J Pharmacol Exp
Ther 1993;265(3):1421-8.
5. Sadzuka Y, Shoji T, Takino Y. Effect of cisplatin on the activities
of enzymes which protect against lipid peroxidation.
Biochem Pharmacol 1992;43(8):1872-5.
6. Winston JA, Safirstein R. Reduced renal blood flow in early
cisplatin-induced acute renal failure in the rat. Am J
Physiol 1985;249:F490-6.
7. Pavao dosSantos OF, Boim MA, Barros EJG, Schor N. Role of
Platelet Activating Factor in gentamicin and cisplatin
nephrotoxicity. Kidney Int 1991;40:742-7.
8. Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM,
Hande KR. The role of the renin-angiotensin system in
cisplatin nephrotoxicity. Ren Fail 1995;17(6):665-74.
9. Kurt E, Manavoglu O, Dilek K, Orhan B, Evrensel T. Effect of
cisplatin on plasma renin activity and serum aldosteron
levels. Clin Nephrol 1999;52(6):397-8.
10. Robert A. Protection against mucosal damage: Mechanism of
action of eicosanoids. In: Hillier K (ed). Eicosanoids and
the Gastrointestinal Tract. Lancester: MTP Press LTD;
1988. pp103-10.
11. Tarnowski A, Brzozowski T, Sarfeh IJ, Krause WJ, Ulich TR,
Gergely H, Hollander D. Prostaglandin protection of
human isolated gastric glands against indomethacin and
ethanol injury. Evidence for direct cellular action of
prostaglandin. J Clin Invest 1988;81:1081-9.
12. Terano A, Mach T, Stachura J, Tarnowski A, Ivey KJ. Effect of
16,16 dimethyl prostaglandin E2 on aspirin-induced
damage to rat gastric epithelial cells in tissue culture. Gut
1984;25:19-25.
13. Nesher G, Sonnenblick M, Dwolatzky T. Protective effect of
misoprostol on indomethacin induced renal dysfunction in
elderly patients. J Rheumatol. 1995;22(4):713-6.
14. John EG, Fornell LC, Radhakrishnan J, Anutra-Kulchai S,
Jonasson O. The effect of prostaglandin E1 analog
misoprostol on chronic cyclosporine nephrotoxicity. J Pediatr Surg 1993;28(11):1429-32.
15. Paller MS, Manivel JC, Patten M, Barry M. Prostaglandins
protect kidneys against ischemic and toxic injury by a
cellular effect. Kidney Int 1992;42:1345-54.
16. Takayama K, Nakanishi Y, Takano K, Harada T, Inoue K, Osaki
S, Minami T, Hara N. Preventive effect of Prostaglandin E1
on cisplatin-induced nephrotoxicity. Gan To Kagaku
Ryoho 1999;26(4):503-8.
17. Ikeguchi M, Maeta M, Kaibara N. Cisplatin combined with
prostaglandin E1 chemotherapy in rat peritoneal
carcinomatosis. Int J Cancer 2000;88(3):474-8.
18. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review.
Cancer Chemother Pharmacol 1989;25:1-9.
19. Singh G. A possible cellular mechanism of cisplatin-induced
nephrotoxicity. Toxicology 1989;58:71-80.
20. Soejima A, Inoue T, Suzuki M, Waku M, Nakabayashi K,
Kitamoto K, Nagasawa T. Clinical investigation of cisplatinum nephrotoxicity in 244 cases of primary lung
cancer. Nippon Jinzo Gakkai Shi 1992;34(7):801-6.
21. Higuchi K, Negoro Y, Suzuki M, Noguchi M, Nakanishi M,
Ishihara M, Nakano M. Acute nephrotoxicity by cisplatin
on tubular damage. Gan To Kagaku Ryoho 1991;18(1):85-
9.
22. Verplanke AJW, Herber RFM, de Vit R, Veenhof CHN.
Comparision of renal function parameters in the
assessement of cisplatin induced nephrotoxicity. Nephron
1994;66:267-72.
23. Fullerton T, Sica DA, Blum RA. Evaluation of the renal
protective effect of misoprostol in elderly, osteoarthritic
patients at risk for nonsteroidal anti-inflammatory druginduced renal dysfunction. J Clin Pharmacol
1993;33:1225-32.
24. Pouteil-Noble C, Chapuis F, Berra N, Hadj-Aissa A, Lacavalerie
B, Lefrancois N, Martin X, Touraine JL. Misoprostol in
renal transplant recipients: a prospective, randomized,
controlled study on the prevention of acute rejection
episodes and cyclosporine A nephrotoxicity. Nephrol Dial
Transplant 1994;9(5):552-5.
25. Davies C, Forrester SD, Troy GC, Saunders GK, Shell LG,
Johnston SA. Effects of a prostaglandin E1 analogue,
misoprostol, on renal function in dogs receiving
nephrotoxic doses of gentamicin. Am J Vet Res
1998;59(8):1048-54.
26. Natov S, Schmitt F, Ikeni A, Lacour B, Hannedouche TP.
Opposite renal effects of a prostaglandin E1 analog and
prostacycline in humans. Kidney Int 1994;45:1457-64.
27. Wong F, Massie D, Hsu P, Dudley F. Dose-dependent effects of
oral misoprostol on renal function in alcoholic cirrhosis.
Gastroenterology 1994;106;658-63.

Thank you for copying data from http://www.arastirmax.com